The unexpected Fiscal Deficit target for FY25, set at 5.1% of the GDP, pleasantly surprised the market, which had anticipated a higher figure. Keeping such an aggressive target has several positive implications for the market.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the